Discontinuation of an alpha-1 blocker or 5-alpha-reductase inhibitor after combination medical treatment in patients with benign prostatic hyperplasia

Tzu Chi Medical Journal

Volumn 18, Issue 2, 2006, Pages

  Liaw, Yuan Ming ^a   Kuo, Hann Chorng ^a  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

BPH; Lower urinary tract symptoms; Medical treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PROSTATE HYPERTROPHY; UROFLOWMETRY;

EID: 33745057736     PISSN: 10163190     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of enign prostatic obstruction. Eur Urol 1999; 36:1-13.
2. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998; 160:1358-1367.
3. Roehrborn CG, Boyle P, Bergner D, et al: Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54:662-669.
4. Gormly GJ, Stoner E, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327:1185-1191.
5. McConnell JD, Roehrborn CG, Bautista OM, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
6. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen OB: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha-reductase inhibitor dutasteride. Eur Urol 2003; 44:461-466.
7. Boyle P, Gould AL, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
8. Boyle P, Roehrborn CG, Marks LS, Vela-Navarette R, Nickel JC: The novel dual 5α-reductase inhibitor dutasteride is effective for the treatment and prevention of complications in men with a PV 30- <40 cc and >40 cc. Eur Urol Suppl 2003; 2:160.
9. Barry MJ, Fowler FJ Jr, O'Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148:1549-1557.
10. Kirby RS, Roehrborn C, Boyle P, et al: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61:119-126.
11. Rigatti P, Brausi M, Scarpa RM, et al: A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Diseases 2003; 6:315-323.
12. Anderson JB, Roehrborn CG, Schalken JA, Emberton M: The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. Eur Urol 2001; 39:390-399.
13. Roehrborn CG, McConnell J, Bonilla J, et al: Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13-20.